Buergers Disease Clinical Trials | A Drug Pipeline Analysis Report 2023 |Companies – Antidote Therapeutics, K-STEMCELL, Caladrius Biosciences.

DelveInsight Business Research LLP
(Nevada, Las Vegas) United States, DelveInsight’s “Buerger’s Disease – Pipeline Insight, 2023” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Buerger’s Disease pipeline landscape.

(Nevada, Las Vegas) United States, DelveInsight’s “Buerger’s Disease – Pipeline Insight, 2023” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Buerger’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Buergers Disease Pipeline Report

  • Over 3+ companies and 3+ pipeline drugs in Alpha1-Antitrypsin Deficiency (AATD) pipeline landscape and their anticipated acceptance in the Burgers Disease market would significantly increase market revenue. 

  • Leading Buergers Disease companies developing novel drug candidates to improve the Buergers Disease treatment landscape include Antidote Therapeutics, K-STEMCELL, Caladrius Biosciences, and others.

Phases

DelveInsight’s Report covers around 3+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Buerger’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

  • Promising Buergers Disease  pipeline therapies in various stages of development include Mesenchymal stem cell therapy, ATI-1013, and others 

Buergers Disease Overview

Buerger’s disease also known as Thromboangiitis obliterans is a rare vascular disease in which blood vessels of the hands and feet become blocked. The affected individual may observe pain as early findings or coldness in the fingers. Later findings include fingers or toes that appear pale, red, or bluish; sudden severe pain in the hands and feet; skin ulcers; gangrene, and eventual amputation. A diagnosis to check blockage of blood vessels can be done through plethysmography, Doppler ultrasound of the extremity, or Catheter-based x-ray arteriogram. Blood tests for other causes of inflamed blood vessels (vasculitis) and blocked (occlusion of) blood vessels may be done. The goal of treatment for Buerger’s disease is to control symptoms and prevent the disease from getting worse.

Buergers Disease  Pipeline Analysis: Drug Profile

Mesenchymal stem cell therapy: K-STEMCELL

Mesenchymal stem cell therapy is a drug candidate that improves or treats ischemic ulcers, etc. caused by Burger’s disease. VascoStem, once injected, indirectly vascularizes through the vascular endothelial cell growth factor (VEGF) secreted from VascoStem, and directly restores the damaged tissue. The molecule is in Phase I/II clinical trial for the treatment of Buerger’s Disease. VascoStem has been awarded a rare pharmaceutical product from the Food and Drug Administration (FDA) in May 2016 as a treatment for berger disease, based on the results of Phase I/II clinical trials in Korea. In addition, the European Medicines Agency (EMA) in March 2017, granted orphan drug designation.

Discover more about the emerging Buergers Disease drugs @ Buergers Disease  Treatment Drugs

Buergers Disease Pipeline Therapies and Key Companies

Mesenchymal stem cell therapy: K-STEMCELL

ATI-1013: Antidote Therapeutics

And many others 

Buergers Disease Pipeline Therapeutics Assessment

This segment of the report provides insights about the different Buerger’s Disease drugs segregated based on the following parameters that define the scope of the report, such as:

Major Players in Buerger’s Disease

There are approx. 3+ key companies which are developing therapies for Buerger’s Disease. The companies which have their Buerger’s Disease drug candidates in the most advanced stage, i.e. Phase III include Caladrius Biosciences.

DelveInsight’s Report covers around 3+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Buerger’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

Scope of the Buergers Disease Pipeline Report 

  • Coverage: Global 

  • Key Alpha1 Antitrypsin Deficiency Companies: Antidote Therapeutics, K-STEMCELL, Caladrius Biosciences, and others 

  • Key Buergers Disease Pipeline Therapies: ATI-1013, Mesenchymal stem cell therapy, and others.

  • Find out more about the Buergers Disease   treatment options in development @ Buergers Disease Clinical Trials

Table of Contents

1. Buergers Disease  Introduction

2. Buergers Disease  Executive Summary

3. Buergers Disease  Overview

4. Buergers Disease  Pipeline Therapeutics

5. Buergers Disease  Late-Stage Products (Phase III)

6. Buergers Disease  Mid-Stage Products (Phase  II)

7. Buergers Disease  Early Stage Products (Phase  I/II)

8. Buergers Disease  Preclinical Stage Products

9. Buergers Disease  Discovery Stage Products

10. Buergers Disease  Therapeutic Assessment

11. Buergers Disease  Inactive Products

12. Buergers Disease  Collaborations Assessment- Licensing / Partnering / Funding

13. Buergers Disease  Unmet Needs

14. Buergers Disease  Market Drivers and Barriers

15. Appendix

16. About DelveInsight

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services